The FDA Wants to Approve Vapes Faster. It Never Fixed Why Approving Them Slowly Wasn't Working.

The FDA is expected to announce, within days of this writing, that it will revisit its 2021 premarket tobacco application rule and streamline the scientific-study requirements that currently take years to clear a single vape or nicotine pouch product for legal sale. As of September 1, the agency had authorized 48 e-cigarette products and 43 nicotine pouches out of a market with thousands of unauthorized products still on shelves.

A faster approval line is not the same thing as a safer nicotine market — it’s the same market, just with more legal entrants in it.

Here’s the tension nobody in this fight wants to say plainly: for someone trying to quit combustible cigarettes, a faster path to a regulated nicotine pouch or vape is a genuine harm-reduction win — a legal, tested, lower-risk alternative reaching the market sooner than the current multi-year backlog allows. For a teenager who was never a smoker, the same faster pipeline means more flavored, more marketed, more available nicotine products arriving faster than schools and parents can react to them. The American Lung Association’s objection isn’t wrong that flavor and packaging drive youth uptake. It’s also not an argument against speed — it’s an argument that the FDA has never actually solved the harder problem underneath both positions, which is how to let adult smokers switch faster without also lowering the bar for everyone else.

The FDA’s own authorization numbers show why this is a real bind and not a manufactured one: 91 total authorized products against a submitted-application backlog that has run for years precisely because the agency has been trying, imperfectly, to weigh youth appeal against adult-smoker benefit product by product. Speeding up the process doesn’t resolve that weighing — it just moves through the queue faster while using the same imperfect scale.

If you work with people trying to quit combustible tobacco, the practical read is this: a wider menu of authorized reduced-risk products is coming, sooner than the last few years’ pace suggested. Whether that’s good news depends entirely on who you’re standing next to when it lands — the adult finally getting a legal off-ramp, or the fifteen-year-old who was never on the ramp to begin with.